Ascletis Pharma (HKG:1672) said its phase 1B multiple ascending dose study for its ASC30 tablets for obesity showed positive topline results, according to a Wednesday filing with the Hong Kong bourse.
The drug showed a favorable safety profile, with gastrointestinal-related adverse events mild and short-lived, the filing said.
Trial enrollees did not show serious adverse events, the filing said.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。